V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
The bioprocess business will continue to pioneer contributions to safety and productivity in the manufacture of biotherapeutics
This development is a strategic part of the company's commitment to bolstering its position in the advanced pharmaceutical intermediates segment
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
New facility is part of Aptar Pharma’s global expansion program
High-quality baobab oil sourced in collaboration with UNCCD and the Great Green Wall Initiative
The CAPSUL solution enables optimal process performance for production of premier quality PCL grades at competitive rates
India had proposed for setting up the global standards for millets
The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene
This cell will serve as an extension of the Tele Mental Health Assistance and Networking Across States initiative of the Ministry of Health and Family welfare
Subscribe To Our Newsletter & Stay Updated
